Journal article

Plasminogen activator inhibitor-1 activity in type 2 diabetes - A different relationship with coronary heart disease and diabetic retinopathy

Laima Brazionis, Kevin Rowley, Alicia Jenkins, Catherine Itsiopoulos, Kerin O'Dea

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2008

Abstract

BACKGROUND: Plasminogen activator inhibitor (PAI)-1, a key regulator of fibrinolysis, is associated with increased risk of coronary heart disease (CHD) and is a potential therapeutic target for CHD. However, the relationship between PAI-1 and the most common diabetic microvascular complication, retinopathy, is unclear. The purpose of this study was to assess the relationship between PAI-1 activity and both retinopathy and CHD in type 2 diabetes. METHODS AND RESULTS: We determined PAI-1 activity and both retinopathy (assessed by masked grading of 3-field retinal photographs) and CHD status (assessed by ECG and standard questionnaires) in 147 men and women with type 2 diabetes, mean age (SD) 6..

View full abstract